Rupesh R. Kotecha, MD, discusses a newer radiation modality known as pulse reduced dose rate radiation therapy.
Rupesh R. Kotecha, MD, chief of Radiosurgery and director of Central Nervous System Metastasis at Baptist Health Miami Cancer Institute, discusses a newer radiation modality known as pulse reduced dose rate radiation therapy.
Kotecha co-authored a study that used pulse reduced dose rate radiation therapy and presented the research at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
0:07 | Pulse reduced dose rate radiation therapy is a very specific reirradiation approach, which has been used primarily in the central nervous system space for recurrent primary brain tumors. But it's also been explored in a couple of circumstances outside of the brain itself. Now, this research was previously limited to very few institutions who had experience with using this technique, and also who see this patient volume. Typically, patients with recurrent primary brain tumors traveled to specific centers of excellence or those who have clinical trials. And then sometimes those centers may not have clinical trials that the patient will be eligible for. But then we have a larger experience or volume of patients with that particular need.
0:53 | So, this was developed at a number of institutions, as one of those re-irradiation approaches to try and control the disease after somebody has progressed on multiple lines of systemic therapy. We had previously known at least in the limited series that had been done, that there was some aspect of disease control that looked very favorable, and the order of maybe six months or so longer in some series, shorter and other series.
1:19 | The purpose of our study was to do two things. Number one is to actually incorporate the prior radiation therapy plans, and then add the new reirradiation plans together to come up with those constraints, safety threat thresholds that could be used in the future when patients are undergoing radiation. The second goal was to basically pull the analyses from these different institutions so that we would know what [the] composite outcomes are, not just what does institution A or B, or C actually present or publish. But what happens when you pull all the outcomes together statistically, to look at what those outcomes could be across all of the institutions
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More